Key facts
- INGENIA Therapeutics’s last known valuation is $100.0M.
- It has raised $17.0M across 3 recorded rounds; the latest was Early Stage VC ($5.0M) in Jun 2024.
- Notable investors include TKG Ventures, Seoul Biohub.
- INGENIA Therapeutics has filed 4 Form Ds with the SEC since 2019, most recently Jun 2024 ($5.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for INGENIA Therapeutics
Funding rounds
3 roundsAbout INGENIA Therapeutics
Developer of a therapeutic antibody candidate designed for capillary diseases. The company specializes in discovering and developing antibody candidates for patient populations suffering from defective microvessels and progressive chronic diseases, and focuses on treating damaged capillary-associated indications with high unmet clinical needs, enabling medical professionals to cure damaged capillary functions.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2018
- Employees
- 23
- Website
- ingeniatherapeutics.com/
- Ownership
- Privately Held (backing)
INGENIA Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in INGENIA Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on INGENIA Therapeutics in its N-PORT filings yet. We sweep new filings monthly.